Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07083349Phase 1Terminated
- Sponsor
- Base Therapeutics
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK510 in systemic lupus erythematosus (SLE), sponsored by Base Therapeutics. Primary endpoints: Systemic Lupus Erythematosus Response Index 4 Response Rate at 6 months, Incidence of Treatment-Related Adverse Events at 1 year and 1 more. Started Dec 2025; status: terminated.
02
Drugs
NK510
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07083349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083349.